Adult Dosing

Temporary relief of ocular itchiness and redness

• Instill 1-2 drops in the affected eye(s) qid

Pediatric Dosing

• Safety and effectiveness in pediatric patients <6 yrs of age have not been established

Temporary relief of ocular itchiness and redness

• >6 yrs: Instill 1-2 drops in the affected eye(s) qid

[Outline]

• Adult Dosing
• Pediatric Dosing

• Temporarily relieves ocular itching and redness caused by pollen, ragweed, grass, animal hair and dander

• Hypersensitivity to any of the ingredients of the product
• Angle-closure glaucoma
• Concurrent use or use within 14 days of discontinuing MAO inhibitors

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Avoid touching the eyelids or surrounding areas with the dropper tip as this could contaminate the medication and result in serious ocular infections
• During therapy, pupils may become enlarged temporarily
• Overuse may cause more eye redness
• Discontinue use and consult a physician if irritation and redness of the eye worsens or persists for more than 72 hrs, or if the patient experiences eye pain and/or changes in vision

Cautions: Use cautiously in

• Hypertension
• Hyperthyroidism
• CV disease
• Hyperglycemia (diabetes)
• Urinary tract obstruction
• Prostatic hypertrophy

Supplemental Patient Information

• Advise patients to remove contact lenses before using eye drops
• Inform patients that they may feel a brief tingling after putting in eye drops

Pregnancy Category:C

Breastfeeding: Manufacturer advices caution.

• EENT: Mydriasis, increased redness, irritation, discomfort, transient ocular stinging, blurring, lacrimation, increased IOP, punctate epithelial keratitis
• CNS: Dizziness, headache, nervousness, drowsiness, weakness, CNS depression (patients <6 yrs)
• CV: Hypertension, cardiac irregularities
• GI: Nausea
• DERM: Increased sweating
• ENDO: Hyperglycemia

Naphazoline

• Ophthalmic decongestant (sympathomimetic); reduces ocular congestion and redness by stimulating alpha adrenergic receptors
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

Pheniramine

• Ophthalmic antihistamines and decongestants; antagonizes the pharmacological effects of histamine that are mediated through activation of H1 receptor sites and thereby reduces the intensity of allergic reactions and tissue injury response involving histamine release
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Naphcon-A
• Opcon-A
• Visine-A

US Availability

naphazoline/pheniramine (generic)

• OTC OPTH SOLN: 0.02675%/0.315%
• OTC OPTH SOLN: 0.025%/0.3%

Naphcon-A, Visine-A

• OTC OPTH SOLN: 0.025%/0.3%

Opcon-A

• OTC OPTH SOLN: 0.02675%/0.315%

Canadian Trade Name(s)

• Diopticon A
• Naphcon-A
• Opcon-A
• Visine Advance Allergy

Canadian Availability

Diopticon A, Naphcon-A, Visine Advance Allergy

• OTC OPTH LIQ: 0.025%/0.3%

Opcon-A

• OTC OPTH SOLN: 0.02675%/0.315%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• Naphcon-A
• Visine Allergy with Antihistamine

Australian Availability

Naphcon-A, Visine Allergy with Antihistamine

• OPTH LIQ: 0.25 mg/mL / 3 mg/mL

[Outline]

Ophthalmic

Ophthalmic Antihistamines & Decongestants

Allergy & Immunology

Ophthalmic Antihistamines & Decongestants

Pricing data from www.DrugStore.com in U.S.A.

• Naphcon-A 0.025-0.3 % SOLN [Bottle] (ALCON VISION)
  15 % = $18.99
  45 % = $35.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.